Albendazole

Albendazole is an anthelmintic drug of the benzimidazole class, a group of antiparasitic agents built around a fused double-ring chemical structure ^[1]. It has an unusually broad spectrum of activity, working against many nematodes (roundworms), some cestodes (tapeworms), and certain protozoa, which makes it one of the most versatile deworming medicines available ^[1]. After it is absorbed, it is rapidly converted in the liver to an active form, albendazole sulfoxide, which carries much of its antiparasitic effect ^[1].

The compound was developed in the 1970s and introduced first for veterinary use before being registered for human treatment in the early 1980s ^[1]. In people it is used for common intestinal worm infections such as ascariasis, hookworm, pinworm, and whipworm, and, in longer courses, for more serious diseases in which larvae lodge in body tissues, most importantly cystic and alveolar echinococcosis (hydatid disease) and neurocysticercosis, an infection of the brain by tapeworm larvae ^[1][3]. For echinococcosis it has become a central part of management, used on its own or alongside surgery ^[3].

Albendazole is taken by mouth, often as a chewable tablet, and has a strong safety record across hundreds of millions of treatments, with side effects that are usually mild ^[1]. It is listed by the World Health Organization as an essential medicine and is distributed on a very large scale in community deworming and neglected tropical disease programs, supported by extensive manufacturer donations ^[1]. It is available as an inexpensive generic worldwide ^[1].

Albendazole is prescription only. Short courses are usually mild, with occasional nausea, stomach ache or headache. Longer, higher-dose treatment for tissue infections can raise liver enzymes and, less often, suppress blood counts or cause temporary hair thinning, so liver tests and blood counts are monitored. It is avoided in pregnancy, especially the first trimester, because of possible harm to the baby. When treating neurocysticercosis, killing the cysts can inflame the surrounding brain tissue, so steroids and sometimes anti-seizure drugs are added, and the eyes are checked first for cysts. Dexamethasone, praziquantel and cimetidine can raise its blood levels.

Albendazole is a prodrug; the active species is albendazole sulfoxide, formed largely by CYP3A4 and flavin-containing monooxygenases, so anything that shifts that conversion shifts the effect.

Inducers cut it. Phenytoin, carbamazepine and phenobarbital lower albendazole sulfoxide exposure by roughly a third to a half, which matters a great deal because those anticonvulsants are exactly what neurocysticercosis patients tend to be taking. Ritonavir reduces exposure by around 40%.

Inhibitors raise it, sometimes usefully. Dexamethasone, routinely co-administered to control the inflammatory response to dying cysts, increases albendazole sulfoxide AUC by roughly 250%. Praziquantel raises it as well, and cimetidine does so by prolonging the elimination half-life.

Because higher systemic exposure is generally wanted in tissue infections such as hydatid disease and neurocysticercosis, several of these interactions are exploited rather than avoided; the risk then sits on the side of hepatotoxicity and bone marrow suppression.

Checking a whole stack? Run it through interactions + stacks.

Albendazole is a benzimidazole anthelmintic developed by SmithKline (a corporate ancestor of GlaxoSmithKline), introduced in the late 1970s for veterinary use and subsequently established for human medicine in the following decade. It belongs to the benzimidazole family that grew out of mid-twentieth-century research into agents that disrupt parasite microtubules by binding beta-tubulin. Marketed under names such as Albenza and Zentel, it proved effective across a broad spectrum of worm infections, from common intestinal helminths to serious tissue diseases including neurocysticercosis and hydatid disease. Its combination of low cost, oral dosing, and wide activity made it a mainstay of large-scale deworming programs, and it is listed on the World Health Organization's List of Essential Medicines.

Albendazole is widely respected as a workhorse of global parasitology, valued for being inexpensive, orally administered, and effective against an unusually broad range of parasitic worms. Public-health authorities rely on it heavily in mass deworming campaigns, and its inclusion on the WHO Essential Medicines list reflects a strong track record of benefit at population scale. For single-dose treatment of common intestinal worms it is generally very well tolerated. It is honest to note that serious tissue infections such as hydatid disease and neurocysticercosis require prolonged, higher-dose courses, and that these extended regimens carry a greater need for monitoring, particularly of liver function and blood counts; in that setting it is often paired with other agents to improve parasite clearance.